Applying Risk-Benefit Analysis to Outcomes in TB Clinical Trials.
Although it is common to analyze efficacy and safety separately in clinical trials, this approach could yield a misleading study conclusion if an increase in efficacy is accompanied by a decrease in safety. Risk-benefit analysis is a systematic approach to examine safety and efficacy jointly. Both "rank-based" and "partial-credit" methods described in this paper allow researchers to create a single composite outcome incorporating efficacy, safety, and other factors. The first approach compares the distribution of rankings between arms. In the second approach, a score can be assigned to each outcome category considering its severity and the mean or median scores of arms are compared. The methods were applied to the A5279/BRIEF-TB study and design considerations for future clinical trials are discussed, including the challenge of arriving at a consensus on rankings/scorings. If well-designed, risk-benefit analysis may allow researchers to conduct a superiority comparison and therefore avoid setting a non-inferiority margin. CLINICALTRIAL.GOV IDENTIFIER: NCT01404312 (A5279).